Weight management therapy Poviztra® has become significantly more affordable after Emcure Pharmaceuticals Ltd. announced a major price cut across its dosage range.
The starting dose will now cost Rs. 3,999 per month, down by 55%, making the treatment more accessible to patients seeking medically supervised weight loss solutions.
The drug is delivered through a once-weekly pen device and is available in five strengths, catering to different stages of treatment.
With obesity linked to over 230 health complications, including diabetes and heart disease, affordability has remained a key barrier to treatment in India. The revised pricing is expected to improve adoption rates.
Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, “The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity.3 Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.”
